Norodyl Tablets 20mg for Dogs

Main information

  • Trade name:
  • NOROCARP comprimés 20 mg
  • Pharmaceutical form:
  • Tablet
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • NOROCARP comprimés 20 mg
    France
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • carprofen
  • Therapeutic area:
  • Dogs

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • UK/V/0242/001
  • Authorization date:
  • 12-09-2011
  • EU code:
  • UK/V/0242/001
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

Revised:February2012

AN.01969/2010

Page1of5

SUMMARYOFPRODUCTCHARACTERISTICS

1. NameoftheVeterinaryMedicinalProduct

Norodyl20mgTabletsforDogs(UK)

Norocarp20mgTabletsforDogs(France)

Carprogesic20mgTabletsforDogs(Germany,Belgium,Luxembourg)

2. QualitativeandQuantitativeComposition

Eachtabletcontains:

ActiveIngredient:

Carprofen 20mg

Excipients:

Forafulllistofexcipients,seesection6.1

3. PharmaceuticalForm

Tablet

Awhite/offwhitecirculartabletofdiameter8mm,20embossedonone

sideandasinglebreaklineontheotherside.

4. ClinicalParticulars

4.1 TargetSpecies:

Dogs

4.2 IndicationsforUse,SpecifyingtheTargetSpecies:

Inthedog:Reductionofinflammationandpaincausedbymusculo-

skeletaldisordersanddegenerativejointdisease.Asafollowupto

parenteralanalgesiainthemanagementofpost-operativepain.

4.3 Contraindications:

Donotuseincats.

Donotuseinpuppieslessthan4monthsofage.

Donotuseincaseofhypersensitivitytoactivesubstanceortoanyof

theexcipients.

Donotuseindogssufferingfromcardiac,hepaticorrenaldisease,

wherethereisapossibilityofgastrointestinalulcerationorbleeding,or

wherethereisevidenceofablooddyscrasia.

Refertosection4.7

Revised:February2012

AN.01969/2010

Page2of5

4.4 SpecialWarningsforEachTargetSpecies:

RefertoSections4.3and4.5.

4.5 SpecialPrecautionsforUse:

(i)Specialprecautionsforuseinanimals

Useinageddogsmayinvolveadditionalrisk.Ifsuchusecannotbe

avoided,suchdogsmayrequirecarefulclinicalmanagement.

Avoiduseinanydehydrated,hypovolaemicorhypotensivedog,as

thereisapotentialriskofincreasedrenaltoxicity.

NSAIDscancauseinhibitionofphagocytosisandhenceinthe

treatmentofinflammatoryconditionsassociatedwithbacterialinfection,

appropriateconcurrentantimicrobialtherapyshouldbeinstigated.

Refertosection4.8

SomeNSAIDsmaybehighlyboundtoplasmaproteinsandcompete

withotherhighlybounddrugs,whichcanleadtotoxiceffects.

(ii)Specialprecautionstobetakenbythepersonadministeringthe

veterinarymedicinalproducttoanimals

Intheeventofaccidentalingestionofthetablets,seekmedicaladvice

andshowthedoctorthepackageleaflet.Washhandsafterhandling

theproduct.

4.6 UndesirableEffects(FrequencyandSeriousness):

TypicalundesirableeffectsassociatedwithNSAIDssuchasvomiting,

softfaeces/diarrhea,faecaloccultblood,lossofappetiteandlethargy

havebeenreported.Theseadversereactionsoccurgenerallywithin

thefirsttreatmentweekandareinmostcasestransientanddisappear

followingterminationofthetreatmentbutinveryrarecasesmaybe

seriousorfatal.

Ifadversereactionsoccur,useoftheproductshouldbestoppedand

theadviceofaveterinarianshouldbesought.

AswithotherNSAIDsthereisariskofrarerenaloridiosyncratic

hepaticadverseevents.

4.7 UseDuringPregnancy,LactationorLay:

Studiesinlaboratoryspecies(ratandrabbit)haveshownevidenceof

foetotoxiceffectsofcarprofenatdosesclosetothetherapeuticdose.

Thesafetyoftheveterinarymedicinalproducthasnotbeen

establishedduringpregnancyandlactation.Donotuseinpregnantor

lactatingbitches.

Revised:February2012

AN.01969/2010

Page3of5

4.8 InteractionwithotherMedicinalProductsandOtherFormsof

Interaction:

DonotadministerNSAIDsandglucocorticoidsconcurrentlyorwithin

24hoursofeachother.SomeNSAIDsmaybehighlyboundtoplasma

proteinsandcompetewithotherhighlybounddrugs,whichcanleadto

toxiceffects.

Concurrentadministrationofpotentialnephrotoxicdrugsshouldbe

avoided.

4.9 AmountstobeAdministeredandAdministration:

Fororaladministration.

4mgcarprofenperkgbodyweightperday.

Aninitialdoseof4mgcarprofen/kgbodyweight/daygivenasasingle

dailydoseorin2equallydivideddoses.Thedosemaybereduced

subjecttoclinicalresponse.

Durationoftreatmentwillbedependentupontheresponseseen.Long

termtreatmentshouldbeunderregularveterinarysupervision.

Donotexceedstateddose.

Toextendanalgesicandanti-inflammatorycoverpost-operatively

parenteralpre-operativetreatmentwithaninjectablecarprofenproduct

maybefollowedwithCarprofenTabletsat4mg/kg/dayfor5days.

4.10Overdose(symptoms,emergencyprocedures,antidotes),if

necessary:

Dosesuptothreetimestherecommendeddosagearereportedtobe

withoutadverseeffectindogs.Thereisnospecificantidoteto

carprofenbutgeneralsupportivetherapyasappliedtoclinical

overdosagewithNSAID’sshouldbeapplied.

4.11WithdrawalPeriod(s):

Notapplicable

5. PharmacologicalProperties

Pharmacotherapeuticgroup:Non-steroidalanti-inflammatorydrug

ATCVetCode:QM01AE91

5.1 Pharmacodynamicproperties:

Carprofen,(

)-6-chloro- 

-methylcarbazole-2-aceticacid,isanon-

steroidalanti-inflammatorydrug(NSAID).Itisaderivativeof

phenylpropionicacidandamemberofthearylpropionicacidclassof

NSAIDs.Asarepresentativeofthe2-arylpropionicfamily,itcontainsa

Revised:February2012

AN.01969/2010

Page4of5

chiralcenteratC

ofthepropionicmoietyandtherefore,existsin2

sterioisomericforms,the(+)-Sand(-)-Renantiomers.

Carprofenpossessesanti-inflammatory,analgesicandanti-pyretic

activity.CarprofenlikemostotherNSAIDsisaninhibitorofthe

enzymecyclo-oxygenaseofthearachidonicacidcascade.However

theinhibitionofprostaglandinsynthesisbycarprofenisslightinrelation

toitsanti-inflammatoryandanalgesicpotency.Theprecisemodeof

actionofcarprofenisnotclear.

5.2 Pharmacokineticproperties:

Absorptionisrapidwith>90%absorptionafteroraladministration.The

volumeofdistributionissmallandcarprofenishighlyboundtoplasma

proteins.Biotransformationofcarprofenoccursinthelivertoformthe

esterglucuronideandtwo1-O-acyl- β-D-glucuronidediastereoisomers.

Thesearesecretedinthebiliarytractandexcretedinthefaeces.The

Cmaxis28.51µg/mlandtheAUCis237.33µg/ml.hour.

6. PharmaceuticalParticulars

6.1 ListofExcipient(s):

Microcrystallinecellulose

Lactosemonohydrate

Croscarmellosesodium

PovidoneK30

Sodiumlaurilsulfate

Magnesiumstearate

6.2 Incompatibilities:

None.

6.3 Shelf-Life:

Shelf-lifeoftheveterinarymedicinalproductaspackagedforsale

Tubs:3years

Blisterstrips:2years

6.4 SpecialPrecautionsforStorage:

Donotstoreabove25ºC.

Storeinadryplace.

6.5 NatureandCompositionofImmediatePackaging:

Polypropylenetubswithwhitepolyethylenesnapsecurecaps.

Revised:February2012

AN.01969/2010

Page5of5

PVC/Aluminium/Orientatedpolyamideblisterswithaluminiumlidding

foil.

Packsizes:Blisters

Boxof10blisters,eachblistercontains10tablets.

Packsizes:Tubs

Tubcontaining100tablets.

Notallpacksizesmaybemarketed.

6.6 SpecialPrecautionsfortheDisposalofUnusedVeterinary

MedicinalProductsorWasteMaterialsDerivedFromtheUseof

SuchProducts:

Anyunusedveterinarymedicinalproductorwastematerialsderived

fromsuchveterinarymedicinalproductsshouldbedisposedofin

accordancewithlocalrequirements.

7. MarketingAuthorisationHolder

NorbrookLaboratoriesLimited

StationWorks

CamloughRoad

Newry

Co.Down

BT356JP

NorthernIreland

8. MarketingAuthorisationNumber

Vm02000/4265

9. DateofFirstAuthorisation

October2006.

10. DateofRevisionoftheText

February2012

ProhibitionofSale,Supplyand/orUse

UKauthorisedveterinarymedicinalproduct-UKrequirement

POM-V

4-12-2018

FDA Approves Pexion for Treating Noise Aversion in Dogs

FDA Approves Pexion for Treating Noise Aversion in Dogs

The U.S. Food and Drug Administration announced today that its Center for Veterinary Medicine has approved Pexion (imepitoin tablets) to treat noise aversion in dogs. Dogs with noise aversion are sensitive to loud noises such as fireworks, street/traffic noises, and gun shots.

FDA - U.S. Food and Drug Administration

21-11-2018

Fresenius Kabi Issues Voluntary Nationwide Recall of Sodium Chloride Injection, USP, 0.9% Due to Product Labeling Incorrectly Stating Stoppers Do Not Contain Latex

Fresenius Kabi Issues Voluntary Nationwide Recall of Sodium Chloride Injection, USP, 0.9% Due to Product Labeling Incorrectly Stating Stoppers Do Not Contain Latex

Fresenius Kabi USA is voluntarily recalling 163 lots of Sodium Chloride Injection, USP, 0.9%, 10 mL fill in a 10 mL vial and Sodium Chloride Injection, USP, 0.9%, 20 mL fill in a 20 mL vial to the user level. The product insert states that stoppers for both the 10mL and the 20mL vials do not contain natural rubber latex; the tray label for the two vial sizes and the vial label for the 20mL vial also state that the stoppers do not contain latex. The product is being recalled because the stoppers contain n...

FDA - U.S. Food and Drug Administration

20-11-2018

November 20, 2018: Rochester Man Pleads Guilty to Smuggling Counterfeit Cialis and Viagra into the United States

November 20, 2018: Rochester Man Pleads Guilty to Smuggling Counterfeit Cialis and Viagra into the United States

November 20, 2018: Rochester Man Pleads Guilty to Smuggling Counterfeit Cialis and Viagra into the United States

FDA - U.S. Food and Drug Administration

24-10-2018

G & C Raw, LLC is Expanding Recall to Include All Product Lots Manufactured from February 27, 2018 Through July 20, 2018, Because of Possible Listeria Monocytogenes Health Risk

G & C Raw, LLC is Expanding Recall to Include All Product Lots Manufactured from February 27, 2018 Through July 20, 2018, Because of Possible Listeria Monocytogenes Health Risk

G & C Raw, of Versailles, OH is recalling all products lots manufactured from February 27, 2018 through July 20, 2018, as a precaution because they have the potential to be contaminated with Listeria monocytogenes

FDA - U.S. Food and Drug Administration

22-6-2018

June 20, 2018: Fitchburg Woman and Saugus Man Sentenced for Roles in Counterfeit Steroid Conspiracy

June 20, 2018: Fitchburg Woman and Saugus Man Sentenced for Roles in Counterfeit Steroid Conspiracy

June 20, 2018: Fitchburg Woman and Saugus Man Sentenced for Roles in Counterfeit Steroid Conspiracy

FDA - U.S. Food and Drug Administration

2-5-2018

April 17, 2018: Tampa Resident Sentenced to More Than 20 Years in Federal Prison for Tricare Health Care Fraud Scheme

April 17, 2018: Tampa Resident Sentenced to More Than 20 Years in Federal Prison for Tricare Health Care Fraud Scheme

April 17, 2018: Tampa Resident Sentenced to More Than 20 Years in Federal Prison for Tricare Health Care Fraud Scheme

FDA - U.S. Food and Drug Administration

26-11-2018

Data show that nearly 20% of current 510(k)s are cleared based on a predicate that’s more than 10 years old. That doesn’t mean the products are unsafe. But it does mean that some devices may not be continually improving, which is the hallmark of health te

Data show that nearly 20% of current 510(k)s are cleared based on a predicate that’s more than 10 years old. That doesn’t mean the products are unsafe. But it does mean that some devices may not be continually improving, which is the hallmark of health te

Data show that nearly 20% of current 510(k)s are cleared based on a predicate that’s more than 10 years old. That doesn’t mean the products are unsafe. But it does mean that some devices may not be continually improving, which is the hallmark of health technologies.

FDA - U.S. Food and Drug Administration

4-9-2018

Agenda:  Agenda - CHMP agenda of the 20-23 August 2018 written procedure

Agenda: Agenda - CHMP agenda of the 20-23 August 2018 written procedure

Agenda of CHMP written procedure*20-23 August 2018

Europe - EMA - European Medicines Agency

22-8-2018

After over 20 years of wearing contact lenses, this freelance blogger had an unexpected diagnosis in her left eye:  http://bit.ly/2h2NcHz .pic.twitter.com/ecJErFeiSH

After over 20 years of wearing contact lenses, this freelance blogger had an unexpected diagnosis in her left eye: http://bit.ly/2h2NcHz .pic.twitter.com/ecJErFeiSH

After over 20 years of wearing contact lenses, this freelance blogger had an unexpected diagnosis in her left eye: http://bit.ly/2h2NcHz . pic.twitter.com/ecJErFeiSH

FDA - U.S. Food and Drug Administration

20-7-2018

Agenda:  Agenda - CAT agenda of the 18-20 July 2018 meeting

Agenda: Agenda - CAT agenda of the 18-20 July 2018 meeting

Committee for Advanced Therapies (CAT) agenda for the meeting on 18-20 July 2018

Europe - EMA - European Medicines Agency

29-6-2018

A past diagnosis of asthma is also associated with #COPD in 20% of the cases. Visit  https://bit.ly/1xErH2t  to learn more. #FactFridaypic.twitter.com/JWK672XtdI

A past diagnosis of asthma is also associated with #COPD in 20% of the cases. Visit https://bit.ly/1xErH2t  to learn more. #FactFridaypic.twitter.com/JWK672XtdI

A past diagnosis of asthma is also associated with #COPD in 20% of the cases. Visit https://bit.ly/1xErH2t  to learn more. #FactFriday pic.twitter.com/JWK672XtdI

FDA - U.S. Food and Drug Administration